For Quick Alerts
For Daily Alerts

Wuxi Pharmatech enters into definitive merger agreement

By Religare

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has entered into a definitive Agreement and Plan of Merger with New WuXi Life Science Limited and WuXi Merger Limited, a wholly owned subsidiary of Parent.

Pursuant to the Merger Agreement, Parent will acquire the Company for cash consideration equal to USD 5.75 per ordinary share of the Company and USD 46 per American Depositary Share of the Company, each representing eight Shares, or approximately USD 3.3 billion in aggregate cash consideration. This represents a 16.5 per cent premium over the closing price of USD 39.50 per ADS as quoted by the New York Stock Exchange on April 29, 2015.


Credit Suisse Securities (USA) LLC is serving as the financial advisor to the Special Committee, Willkie Farr & Gallagher LLP is serving as U.S. legal counsel to the Special Committee, Walkers Global is serving as Cayman Islands legal counsel to the Special Committee and Zhong Lun Law Firm is serving as PRC legal counsel to the Special Committee. O'Melveny & Myers LLP is serving as U.S. legal counsel to WuXi.

Story first published: Monday, August 17, 2015, 12:30 [IST]
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'


We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more